TITLE:

Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer.

AUTHOR(S):

Fujimoto, Masakazu; Yoshizawa, Akihiko; Sumiyoshi, Shinji; Sonobe, Makoto; Kobayashi, Masashi; Koyanagi, Itsuko; Aini, Wulamujiang; Tsuruyama, Tatsuaki; Date, Hiroshi; Haga, Hironori

---

CITATION:

Fujimoto, Masakazu ...[et al]. Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer.. Human pathology 2013, 44(8): 1569-1576

ISSUE DATE:

2013-08

URL:

<http://hdl.handle.net/2433/177186>

RIGHT:

© 2013 Elsevier Inc.; This is not the published version. Please cite only the published version.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。

1   Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung
2   cancer

3   Masakazu Fujimoto¹, Akihiko Yoshizawa^{1,2}, Shinji Sumiyoshi¹, Makoto Sonobe³,
4   Masashi Kobayashi³, Itsuko Koyanagi¹, Wulamujiang Aini¹, Tatsuaki Tsuruyama¹,
5   Hiroshi Date³, Hironori Haga¹

6

7   1: Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan

8   2: Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto,
9   Japan

10   3: Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

11

12   Corresponding author: Hironori Haga

13   Address: Department of Diagnostic Pathology, Kyoto University Hospital, 54 Shogoin

14   Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

15   Tel.: +81-75-751-3488

16   Fax: +81-75-751-3499

17   E-mail: haga@kuhp.kyoto-u.ac.jp

18

19   **Key words**

1 IgG4, plasma cell, lung, carcinoma, tissue microarray

2

3 **Running head**

4 IgG4+ plasma cells in lung cancer

5

6

Abstract

Inflammatory cell infiltration in tumor stroma may represent the interaction between the tumor and the immune system. The significance of immunoglobulin (Ig)G4+ plasmacytic infiltration, however, is poorly understood. Here, we analyzed the number of stromal IgG4+ plasma cells and the IgG4/IgG ratio of plasma cells in 294 primary non-small cell lung cancers (NSCLC) using tissue microarray (TMA) and conventional surgical specimens. In TMA, 35 (12%) cases of NSCLC revealed more than 20 IgG4+ plasma cells per high-power field. In surgical specimens, most (97%) of those IgG4+ plasma cell-enriched cases showed obliterative phlebitis or arteritis, one of the key morphologic features of IgG4-related disease, within or at the periphery of the tumor. Clinically, none of the patients showed symptoms associated with IgG4-related systemic diseases. In patients with stage I squamous cell carcinoma, IgG4-enriched stroma was significantly associated with a favorable prognosis ($p = 0.04$). In conclusion, considerable IgG4+ plasma cell infiltration can be seen in a minority of cases of NSCLC, and might contribute to prognostic modulation of NSCLC.

1 Introduction

2 Despite a number of recent studies focused on the tumor microenvironment, the role
3 of plasma cells in cancer is not well understood [1]. The class and subclass of
4 immunoglobulin (Ig) produced by plasma cells are defined primarily by their heavy
5 chain constant domain sequences, which affect the function of the antibody [2]. IgG4,
6 the least abundant subclass in the IgG class, shows weak or negligible binding ability
7 to both C1q and Fcγ receptors compared with the other IgG subclasses, which leads
8 to a limited capacity to activate the classical complement pathway [2,3]. Thus, until
9 recently, it was believed that IgG4 plays only a limited role in immune activation [3]. As
10 a consequence of the current familiarity of IgG4-related diseases (IgG4-RD) to
11 pathologists and the widespread use of anti-IgG4 antibody for immunohistochemical
12 staining, cases of carcinoma accompanied by severe IgG4+ plasma cell infiltration in
13 patients with or without a medical history of IgG4-RD have been identified [4-9],
14 although the prevalence and significance of this phenomenon remain unclear.

15 Differential diagnosis of IgG4-RD and cancers can be problematic, since IgG4-RD
16 often forms tumefactive lesions and peritumoral desmoplastic tissue can mimic
17 IgG4-RD when there is an abundance of IgG4+ plasma cells in a biopsy specimen.

18 Some morphologic findings such as obliterative phlebitis are considered to be rather
19 more specific to IgG4-RD than to cancer, but existing evidence supporting this idea

seems weak [10]. Serum IgG4 concentration is a helpful laboratory finding to differentiate IgG4-RD and cancer, but it is not always elevated in patients with IgG4-RD, while it can be elevated in cancer patients without IgG4-RD [4,8]. In addition, clinicians must keep in mind the possibility of synchronous cancer and IgG4-RD [11].

In this study, we identified cases of lung cancer with stromal IgG4+ plasma cell infiltration using tissue microarray (TMA). We analyzed the clinicopathologic characteristics of these cases to investigate the relevance of lung cancer and IgG4+ plasma cells.

Materials and Methods

TMA

Paraffin-embedded tumor blocks from 363 cases of lung cancer surgically resected from different patients in Kyoto University Hospital between 2001 and 2007 were selected from the electronic pathology files of Kyoto University Hospital for construction of TMA, with the patients' consent. TMAs were constructed by 2 of the authors (A.Y. and S.S.) basically using the approach described by Kononen et al. [12]. Briefly, the most morphologically representative region of the tumor was selected on a hematoxylin and eosin (H&E)-stained slide. Then, a tissue core of 2 mm in diameter was punched out from each donor tumor block using a thin-walled stainless steel

needle for TMA construction (Azumaya, Tokyo, Japan), and arrayed in a recipient paraffin block. Small cell carcinomas, recurrent carcinomas, carcinomas with neoadjuvant chemotherapy and cases with multiple carcinomas (both synchronous and metachronous) were excluded from this study, but were established in TMA for another study (n=45).

Immunohistochemistry

Immunostains against IgG4 and IgG using mouse anti-human IgG4:HRP (MCA2098P; dilution 1:200; AbD Serotec, Oxford, UK) and IgG (immunoglobulin G) (polyclonal; dilution 1:2 of prediluted product; Ventana, Tucson, AZ, USA) were performed on an autoimmunostainer (Ventana XT System Benchmark; Ventana Medical Systems).

Evaluation of immunohistochemistry

In TMA sections, we regarded tumors infiltrated by more than 20 IgG4+ plasma cells per high-power field (HPF) (x40 objective lens with field number 22) as IgG4+ cell-enriched cases, since this criterion is used for diagnosing IgG4-RD in lung biopsy specimens [10]. To calculate the IgG4/IgG ratio in each TMA section, the total numbers of IgG4+ and IgG+ plasma cells per core were counted manually under a

light microscope by M.F. and A.Y. For those IgG4+ cell-enriched cases with >25% IgG4/IgG ratio, immunohistochemistry for IgG4 and IgG was performed on the original surgical specimens to extract the cases fulfilling the quantitative criteria for IgG4-RD (>50/HPF of plasma cells with IgG4/IgG ratio >40%) [10]. In each case, IgG4 and IgG were counted in the region most highly stained for IgG4 in three HPFs to calculate the IgG4/IgG ratio.

Histologic evaluation

Histologic types of lung cancers were determined according to the 2004 WHO classification [13]. In adenocarcinomas, the predominant histologic subtype or variant in each case was identified according to the new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society (IASLC/ATS/ERS classification) [14], and it was also graded as well differentiated (G1), moderately differentiated (G2) and poorly differentiated (G3) based on the 2004 WHO classification by three of the authors (M.F., A.Y. and S.S.) [13]. Squamous cell carcinomas were not graded in this study, since the stage of the disease and the performance status at diagnosis remain the most powerful prognostic indicators, instead of the current grading system mainly based on the degree of keratinization [13]. IgG4+ cell-enriched cases were

evaluated by two of the authors (M.F. and A.Y.) for the presence of obliterative phlebitis/arteritis and increased number of eosinophils, which we defined as more than 50 eosinophils per 10 HPFs.

Clinical information

The electronic chart of Kyoto University Hospital, the electronic database of the Department of Thoracic Surgery of Kyoto University Hospital and the electronic pathology database of Kyoto University Hospital were used to search for patients' prognosis and medical history.

Somatic *EGFR*, *KRAS* and *p53* mutations

EGFR, *KRAS* and *p53* mutation analyses were carried out in selected cases by methods described previously [15,16].

Statistical analysis

GraphPad Prism (GraphPad Software, San Diego, CA, USA) and JMP Start Statistics (Statistical Discovery Software SAS Institute, Cary, NC, USA) were used for statistical analyses. Comparisons between two groups were performed with Fisher's exact test or Mann-Whitney's test to analyze categorical variables and continuous

variables, respectively. The Kaplan-Meier method was used to evaluate patients' prognosis and log-rank tests were used to compare the survival rates among groups. Logistic regression analysis was performed to examine the interaction of the multiple clinicopathological variables. Significance was defined as $p < 0.05$.

Results

TMA cores that were not completely enclosed on the sections or did not include viable tumor on the sections were excluded from this study ($n=24$). As a result, 294 primary non-small cell lung carcinomas (NSCLC) were extracted. The median follow-up period of patients was 1748 days (range: 7-3805).

The 294 lung cancers consisted of 233 adenocarcinomas (79.3%), 52 squamous cell carcinomas (17.7%) and 9 other NSCLC (3.1%) (6 large cell carcinomas, 2 sarcomatoid carcinomas and 1 adenosquamous carcinoma). According to the 7th UICC TNM classification [17], 215 cases (73.1%) were stage I, 37 cases (12.6%) were stage II, 31 cases (10.5%) were stage III and 11 cases (3.7%) were stage IV. Among the 233 adenocarcinomas, 60 cases (25.8%) were G1, 90 cases (38.6%) were G2 and 83 cases (35.6%) were G3. The median numbers of IgG4+ and IgG+ plasma cells in the TMA core were 0 (range: 0-570) and 134 (range: 0-2178),

1 respectively. None of the 294 patients had IgG4-RD in their medical history and serum
2 IgG4 concentration was not measured in any of the patients.

3 In adenocarcinomas, mutation analysis of *EGFR*, *KRAS* and *p53* was performed in
4 213 cases, 213 cases and 129 cases, respectively, and the mutation was confirmed in
5 102 cases (47.9%), 23 cases (10.8%) and 31 cases (24.0%), respectively.

6

7 **Lung cancers with IgG4+ cell enrichment (n=35)**

8 Out of 294 cases, 35 cases (11.9%) were IgG4+ cell-enriched, including 17
9 adenocarcinomas (7.3% of all adenocarcinomas), 17 squamous cell carcinomas
10 (32.7% of all squamous cell carcinomas) and 1 adenosquamous carcinoma. Among
11 the 17 adenocarcinomas, 15 cases were G3 and 2 were G2. G1 adenocarcinoma was
12 not observed.

13 The median number of original tumor slides observed per case was 3 (range: 1-9)
14 and Victoria blue H&E stain and/or Elastica van Gieson stain was performed in all but
15 1 case. Fibrosis was evident in cancer stroma of all 35 cases, but none of them
16 showed storiform pattern fibrosis. Obliterative phlebitis/arteritis was found in 34 cases
17 (97.1%) associated with desmoplasia. An increased number of eosinophils was seen
18 in 3 cases (8.6%). In all 35 cases, pathological change for which IgG4-RD was
19 suspected was absent in non-neoplastic lung tissue surrounding the cancers.

The result of comparison between IgG4+ cell-enriched cases and the cases with ≤ 20 IgG4+/HPF in the TMA core is shown in Table 1. We also performed multivariate logistic regression analysis to determine which factors, among those showing statistical significance in univariate analysis, were more significantly associated with >20 /HPF IgG4+ plasma cell infiltration (Table 2). This analysis revealed that squamous cell carcinoma and G3 adenocarcinoma were associated with >20 /HPF IgG4+ plasma cell infiltration with high statistical significance ($p < 0.0001$ and $p = 0.0013$, respectively).

No statistical difference in recurrence rate or death rate was observed between the two groups (Table 1). In stage I carcinoma, however, none of the 19 IgG4+ cell-enriched cases (10 G2-G3 adenocarcinomas, 8 squamous cell carcinomas and 1 adenosquamous carcinoma) was associated with patient death, and only 1 squamous cell carcinoma and 1 adenocarcinoma recurred. In contrast, among 27 stage I squamous cell carcinomas with ≤ 20 IgG4+ plasma cells/HPF, 10 patients (37.0%) died of disease and 11 cases (40.7%) recurred. Among 110 stage I G2-3 adenocarcinomas with ≤ 20 IgG4+ plasma cells/HPF, 13 patients (11.8%) died of disease and 29 cases (26.4%) recurred. A significant difference of overall patient survival was observed in stage I squamous cell carcinoma ($p = 0.0409$), but this was not the case for disease-free survival rate ($p = 0.1053$) (Figure 1). No significant

difference in overall survival or disease-free survival rate was observed in stage I
G2-3 adenocarcinoma ($p=0.3280$ and $p=0.4407$, respectively).

Lung cancers with >50 IgG4+ plasma cells/HPF and >40% IgG4/IgG plasma cells in surgical specimens (n=6)

Among 35 IgG4+ cell-enriched cases in the TMA core, 12 cases were associated
with >25% IgG4/IgG ratio, and 6 of them showed >50 IgG4+ plasma cells/HPF and
>40% IgG4/IgG ratio in the surgical specimens. The clinicopathological features of
these 6 cases are summarized in Table 3. Histologic figures of selected cases are
shown in Figure 2.

In comparison of these 6 cases and the other 29 IgG4+ cell-enriched cases, no
statistically significant difference was obtained in any parameters shown in Table 1,
except the IgG4/IgG ratio in the TMA core (median: 0.28 vs. 0.12, $p=0.0062$).
Additionally, the numbers of cases with obliterative phlebitis/arteritis and increased
number of eosinophils in these 2 groups did not differ significantly (83.3% vs. 100%,
 $p=0.1714$, and 16.7% vs. 6.9%, $p=0.4417$, respectively).

Discussion

IgG4+ plasma cell infiltration in cancer and its relevance to IgG4-RD have been a

1 matter of debate in the field of practical medicine [4-9]. Since chronic inflammation is
2 associated with a risk of cancer development, it could be hypothesized that IgG4-RD
3 is a source of carcinoma [11,18]. In our series, however, the idea that the patients with
4 IgG4+ cell-enriched tumor had lung IgG4-RD seems unlikely for two main reasons.
5 Firstly, none of the IgG4+ cell-enriched cases showed histology of IgG4-RD in the
6 non-neoplastic lung tissue, suggesting that the cancer is the factor causing the
7 inflammation and not the other way round. Secondly, although IgG4-RD is a systemic
8 disease and the affected patients commonly develop multi-visceral lesions or multiple
9 lesions in the same organ at the time of diagnosis or during the follow-up [6,19], none
10 of the patients in our series was clinically complicated by IgG4-RD at the time of
11 diagnosis or during the follow-up of cancer.

12 Considering the favorable prognosis observed in IgG4-enriched stage I squamous
13 cell carcinomas, IgG4 infiltration might cause prognostic modulation of NSCLC. At first,
14 this result seemed to be inconsistent with the notable anti-immune function of IgG4,
15 as seen in the transition of serum IgG4 level in immunotherapy [20]. Other previous
16 reports, however, show that the functional role of IgG4 varies in different
17 pathophysiological circumstances, and that IgG4 can be a pathogenic antibody in
18 certain immunologic disorders [21-25]. Our data may suggest that IgG4 reacts against
19 certain lung cancer antigens and damages tumor cells in spite of its poor complement-

1 and leucocyte-activating properties. By multivariate analysis, we found that squamous
2 cell carcinomas and high-grade adenocarcinomas are more likely to be accompanied
3 by intra-tumoral IgG4+ plasma cells; however, the reason for this tendency is unclear
4 at present.

5 In stage I squamous cell carcinoma, intra-tumoral IgG4+ plasma cell infiltration may
6 be a better prognostic factor than conventional histological grade because the
7 histological grade of lung squamous cell carcinoma is not clearly related to its
8 prognosis [13]. IgG4+ plasma cells might have a cancer-inhibiting role in
9 adenocarcinomas as well, but our data did not show statistical significance. In
10 adenocarcinomas, high-grade histology or non-EGFR gene mutation may be a more
11 powerful prognostic factor than IgG4+ cell infiltration [15,16,26].

12 A common histological finding of IgG4-RD is sclerosing fibrosis arranged at least
13 focally in a storiform pattern accompanied by marked IgG4+ plasma cell infiltration,
14 usually associated with obliterative phlebitis; however, there is variability in the
15 findings in certain organs [10]. In lung IgG4-RD, storiform-type fibrosis is uncommon;
16 thus, histological findings tend to overlap with other pulmonary fibroinflammatory
17 conditions. In the pericancerous fibrous stroma of our IgG4+ cell-enriched cancers,
18 even obliterative phlebitis/arteritis, the histological finding of which is believed to be
19 quite specific to lung IgG4-RD, was observed in most of the cases. Pathologists

1   should be aware of this fact when diagnosing lung IgG4-RD on biopsy specimens.

2   In conclusion, a non-negligible minority of cases of squamous cell carcinoma and
3   high-grade adenocarcinoma of the lung showed IgG4+ plasma cell infiltration in the
4   stroma. Obliterative vascular changes were commonly seen in those cases without
5   clinical evidence of IgG4-RD. Since IgG4+ cell-enriched cases were associated with
6   favorable prognosis in stage I squamous cell carcinomas, IgG4 infiltration may be part
7   of the anti-cancer immune response.

8

1   **References**

- 2   1. Bremnes RM, Al-Shibli K, Donnem T, et al. The role of tumor-infiltrating immune
3   cells and chronic inflammation at the tumor site on cancer development, progression,
4   and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 2011; 6:
5   824-33.
- 6   2. Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of
7   a unique immunoglobulin subtype. Curr Opin Rheumatol 2011; 23: 119-24.
- 8   3. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366:
9   539-51.
- 10   4. Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of
11   autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J
12   Gastroenterol 2007; 102: 1646-53.
- 13   5. Witkiewicz AK, Kennedy EP, Kenneyon L, Yeo CJ, Hruban RH. Synchronous
14   autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case
15   report and review of the literature. Hum Pathol 2008; 39: 1548-51.
- 16   6. Zen Y, Inoue D, Kitao A, et al. IgG4-related lung and pleural disease: a
17   clinicopathologic study of 21 cases. Am J Surg Pathol 2009; 33: 1886-93.

- 1
- 2 7. Strehl JD, Hartmann A, Agaimy A. Numerous IgG4-positive plasma cells are
- 3 ubiquitous in diverse localised non-specific chronic inflammatory conditions and need
- 4 to be distinguished from IgG4-related systemic disorders. *J Clin Pathol* 2011; 64:
- 5 237-43.
- 6 8. Oseini AM, Chaiteerakij R, Shire AM, et al. Utility of serum immunoglobulin G4 in
- 7 distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma.
- 8 *Hepatology* 2011; 54: 940-8.
- 9 9. Tian W, Yakirevich E, Matoso A, Gnepp DR. IgG4+ plasma cells in sclerosing
- 10 variant of mucoepidermoid carcinoma. *Am J Surg Pathol* 2012; 36: 973-9.
- 11 10. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of
- 12 IgG4-related disease. *Mod Pathol* 2012; 25, 1181-1192.
- 13 11. Yamamoto M, Takahashi H, Tabeya T, et al. Risk of malignancies in IgG4-related
- 14 disease. *Mod Rheumatol* 2012; 22:414-8.
- 15 12. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for
- 16 high-throughput molecular profiling of tumor specimens. *Nat Med* 1998; 4: 844-7.

- 1   13. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and
2   genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
- 3   14. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of
4   lung cancer/american thoracic society/european respiratory society international
5   multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:
6   244-85.
- 7   15. Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth
8   factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J
9   Cancer 2005; 93: 355-63.
- 10   16. Sonobe M, Kobayashi M, Ishikawa M, et al. Impact of KRAS and EGFR gene
11   mutations on recurrence and survival in patients with surgically resected lung
12   adenocarcinomas. Ann Surg Oncol 2012; 19(Suppl 3): S347-54.
- 13   17. Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. TNM classification of
14   malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 2009.
- 15   18. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ. The role of Inflammation
16   in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 2010; 5: 2024-36.

- 1 19. Yamashita K, Haga H, Kobashi Y, Miyagawa-Hayashino A, Yoshizawa A, Manabe
- 2 T. Lung involvement in IgG4-Related lymphoplasmacytic vasculitis and interstitial
- 3 fibrosis: report of 3 cases and review of the literature. Am J Surg Pathol 2008; 32:
- 4 1620-6.
- 5 20. Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg
- 6 allergy in children. N Engl J Med 2012; 367: 233-43.
- 7 21. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheifflinger F.
- 8 IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired
- 9 thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7: 1703-10.
- 10 22. Sitaru C, Mihai S, Zillikens D. The relevance of the IgG subclass of autoantibodies
- 11 for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res 2007;
- 12 299: 1-8.
- 13 23. Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy
- 14 due to cationic bovine serum albumin. N Engl J Med 2011; 364: 2101-10.
- 15 24. Beck LH, Jr, Salant DJ. Membranous nephropathy: recent travels and new roads
- 16 ahead. Kidney Int 2010; 77: 765-70.

- 1 25. Holland M, Hewins P, Goodall M, Adu D, Jefferis R, Savage CO. Anti-neutrophil
- 2 cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible
- 3 pathogenic role for the IgG4 subclass. Clin Exp Immunol 2004; 138: 183-92.
- 4 26. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS
- 5 classification of lung adenocarcinoma: prognostic subgroups and implications for
- 6 further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;
- 7 24: 653-64.

8

9

10

11

12

13

14

15

1   **Table legends**

2

3   Table 1. Comparison of lung cancers with and without >20 IgG4+ plasma cells/HPF in
4   the tissue microarray (TMA) core (n=294).

5

6   Table 2. Logistic regression analysis for estimation of significant factors related to
7   >20/HPF intra-tumoral IgG4+ plasma cell infiltration.

8

9   Table 3. Clinicopathological characteristics of 6 lung cancers that fulfilled the
10   histological criteria of lung IgG4-RD (IgG4/IgG ratio >40% and >50/HPF IgG4+
11   plasma cells in surgical specimen).

12

Table 1

	Number of IgG4+ plasma cells/TMA core		p
	>20/HPF	≤20/HPF	
No. of cases	35 (11.9%)	259 (88.1%)	
Median of IgG4/IgG ratio in TMA core (range)	0.13 (0.021-0.47)	0 (0-0.75)	<0.0001*
Male	30 (85.7%)	144 (55.6%)	0.0005*
Median age (range)	72 (41-88)	67 (23-94)	0.1783
Never smokers	4 (11.4%)	107 (41.3%)	0.0004*
Preoperative history of cancer	7 (20.0%)	48 (18.5%)	0.8189
Preoperative history of asthma	4 (11.4%)	8 (3.1%)	0.0417*
Preoperative history of collagen vascular disease	1 (2.8%)	9 (3.5%)	1
Preoperative history of interstitial pneumonia	1 (2.9%)	15 (5.8%)	0.7032
Squamous cell carcinomas	17 (48.6%)	35 (13.5%)	<0.0001*
G3 adenocarcinomas	15 (42.9%)	68 (26.3%)	0.0468*
Gene mutation in adenocarcinomas	EGFR 3/14 (21.4%)	EGFR 99/199 (49.0%)	0.0524
	KRAS 1/14 (7.1%)	KRAS 22/199 (11.1%)	1
	p53 5/7 (71.4%)	p53 26/122 (21.3%)	0.0088*
Stage I cancers	19 (54.3%)	196 (75.7%)	0.0134*
Recurrence rate (Recurrence rate of stage I cancers)	34.3% (10.5%)	32.8% (20.9%)	0.8502 (0.3773)
Death rate (Death rate of stage I cancers)	20.0% (0%)	22.8% (12.2%)	0.8111 (0.1395)

* Statistically significant.

Table 2

Variable	Odds ratio	95% confidence interval	p
Sex (Male/Female)	1.8285	0.5631-6.9714	0.3392
Smoking history (Never/Current or Former)	0.6118	0.1400-2.2837	0.4829
Preoperative history of asthma (present/absent)	2.7665	0.6253-11.2757	0.1581
Squamous cell carcinoma	15.4307	4.5863-71.6024	<0.0001*
G3 adenocarcinoma	8.5662	2.5946-38.8643	0.0013*
Cancer stage (Stage I/Stage II-IV)	0.6655	0.2968-1.4987	0.3215

* Statistically significant.

Table 3

Case No.	1	2	3	4	5	6
Sex	Male	Male	Male	Male	Male	Male
Age at surgery	59	61	61	65	72	75
Smoking status	Current	Former	Former	Former	Never	Current
Past medical history	None	Hypopharyngeal squamous cell carcinoma	None	Asthma, Hepatitis C	Diabetes mellitus, Arrhythmia	Colon carcinoma, Renal carcinoma (histology not available)
Site	Right upper lobe	Left upper lobe	Right lower lobe	Right upper lobe	Left upper lobe	Left lower lobe
Stage	1B (T2aN0M0)	1A (T1aN0M0)	1A (T1bN0M0)	1B (T2aN0M0)	2A (T1bN1M0)	1A (T1aN0M0)
Histology	Adenosquamous carcinoma	Adenocarcinoma, solid predominant, G3	Squamous cell carcinoma	Squamous cell carcinoma	Adenocarcinoma, micropapillary predominant, G3	Squamous cell carcinoma
Obliterative phlebitis/arteritis	Present	Present	Absent	Present	Present	Present
Eosinophilic infiltration >50/10 HPF	Absent	Absent	Absent	Present	Absent	Absent
IgG4/IgG ratio in TMA core (%)	206/820 (25.1)	570/1204 (47.3)	172/625 (27.5)	258/1012 (25.5)	216/648 (33.3)	348/1211 (28.7)
IgG4/IgG ratio in surgical specimen (%)	51.7/103.7 (49.9)	80.0/137.0 (58.4)	67.7/146.7 (46.1)	53.3/125.3 (42.5)	69.7/170.7 (40.8)	50.6/105.3 (48.1)
EGFR	Not done	Wild	Wild	Wild	Mutated	Wild
KRAS	Not done	Mutated	Wild	Wild	Wild	Wild
p53	Not done	Not done	Mutated	Wild	Not done	Wild
Recurrence of lung carcinoma	Absent	Absent	Absent	Absent	Present	Absent
Outcome	Alive	Alive	Alive	Alive	Died of disease	Alive
Follow-up period (days)	3480	1666	2747	2002	376	1468

Figure legends

Figure 1 Kaplan-Meier survival curves of 35 patients with stage I squamous cell carcinomas separated by the number of IgG4+ plasma cells/HPF in the tissue microarray core ($>20/\text{HPF}$ vs. $\leq 20/\text{HPF}$). (A) Overall survival curves (log-rank test, $p=0.0409$), and (B) disease-free survival curves (log-rank test, $p=0.1053$).

Figure 2 Histology of lung cancers fulfilling the histological criteria for lung IgG4-RD, (A)-(E) case 2 and (F)-(H) case 4.

(A) Case 2, solid predominant G3 adenocarcinoma ($\times 20$).

(B) Higher-magnification image of boxed area in (A) ($\times 100$).

(C) Intratumoral obliterative phlebitis ($\times 100$).

(D) $>50/\text{HPF}$ IgG4+ plasma cells in the cancer stroma ($\times 200$).

(E) IgG immunostain at the same area as in (D), with IgG4/IgG ratio $>40\%$ ($\times 200$).

(F) Case 4, squamous cell carcinoma ($\times 40$).

(G), (H) Higher magnification of the areas demarcated by boxes in (F); obliterative vasculitis and eosinophilic infiltration are shown, respectively ($\times 200$ and $\times 400$).

Figure 1(A)

Figure 1(B)

Figure 2(A)

Figure 2(B)

Figure 2(C)

Figure 2(D)

Figure 2(E)

Figure 2(F)

Figure 2(G)

Figure 2(H)